868 results on '"Faries, Mark"'
Search Results
2. Supporting Sustainable Health Behavior Change: The Whole is Greater Than the Sum of Its Parts
3. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
4. Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
5. Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
6. Commentary re PRADO: De-escalation in Melanoma After Neoadjuvant Therapy: When to Cut and When to Cut Back
7. An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma
8. Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II)
9. Sentinel Lymph Node Mapping in Non-small Cell Lung, Colon, and Thyroid Carcinomas
10. Regional Melanoma Therapy: Positive Sentinel Lymph Node
11. Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
12. Acute and Repeated Ashwagandha Supplementation Improves Markers of Cognitive Function and Mood
13. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
14. Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)
15. Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma
16. Donald L. Morton Memorial Lecture: the legacy of Donald Morton: past, present and future
17. The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis
18. Paraxanthine provides greater improvement in cognitive function than caffeine after performing a 10-km run
19. Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial
20. Integrating autonomy in public health messaging
21. Surgical Management of Distant Melanoma Metastases
22. Biopsy of the Sentinel Lymph Node
23. Destroying God's Temple? Physical Inactivity, Poor Diet, Obesity, and Other "Sin" Behaviors
24. Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma
25. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
26. Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma
27. ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma
28. ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II
29. ASO Author Reflections: Minimally Invasive Inguinal Lymphadenectomy, an Incremental Step in the Evolution of the Management of Advanced Melanoma
30. Health Coaching, Motivational Interviewing, and Behavior Change in Women's Health
31. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
32. Sentinel Lymph Node Biopsy: Indications and Technique
33. Immunohistochemistry for Preferentially Expressed Antigen in Melanoma in the Differential Diagnosis of Melanocytic Lesions of the Nail Apparatus
34. Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma
35. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
36. A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II)
37. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease
38. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)
39. Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis
40. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
41. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
42. Systemic Therapy for Melanoma: ASCO Guideline Update
43. Regional Melanoma Therapy: Positive Sentinel Lymph Node
44. Letter Regarding Editorial by Samuel Zagarella
45. Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?
46. Different impacts of resources on opposite sex ratings of physical attractiveness by males and females
47. Comparative Evaluation of [99mTc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials
48. Future perspectives in melanoma research. Meeting report from the ¿Melanoma Bridge. Napoli, December 2nd-4th 2012¿
49. Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival
50. Microsatellitosis in Patients with Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.